Açıklama
Safety and secondary outcome measures from the Bacillus clausii probiotic trial in pediatric acute diarrhea, comparing adverse event rates and recovery milestones between the probiotic and placebo groups.
Figure 3
ChartSource Paper
Efficacy and safety of Bacillus clausii (O/C, N/R, SIN, T) probiotic combined with oral rehydration therapy (ORT) and zinc in …Tropical diseases, travel medicine and vaccines (2022)
PMID: 35397572
Cite This Figure
![Figure 3: Safety and secondary outcome measures from the Bacillus clausii probiotic trial in pediatric acute diarrhea, comparing adverse event rates and recovery milestones between the probiotic and placebo groups.]() > Source: Keya Rani Lahiri et al. "Efficacy and safety of Bacillus clausii (O/C, N/R, SIN, T) probiotic combined wi." *Tropical diseases, travel medicine and vaccines*, 2022. PMID: [35397572](https://pubmed.ncbi.nlm.nih.gov/35397572/)
<figure> <img src="" alt="Safety and secondary outcome measures from the Bacillus clausii probiotic trial in pediatric acute diarrhea, comparing adverse event rates and recovery milestones between the probiotic and placebo groups." /> <figcaption>Figure 3. Safety and secondary outcome measures from the Bacillus clausii probiotic trial in pediatric acute diarrhea, comparing adverse event rates and recovery milestones between the probiotic and placebo groups.<br> Source: Keya Rani Lahiri et al. "Efficacy and safety of Bacillus clausii (O/C, N/R, SIN, T) probiotic combined wi." <em>Tropical diseases, travel medicine and vaccines</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35397572/">35397572</a></figcaption> </figure>